Wells, Samuel A <br/><br/>
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Feb 2010 
 - 767-72 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2009.23.6604  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Biomarkers, Tumor--blood<br/>Calcitonin--blood<br/>Carcinoembryonic Antigen--blood<br/>Carcinoma, Medullary--drug therapy<br/>Disease-Free Survival<br/>Drug Administration Schedule<br/>Female<br/>France<br/>Genetic Predisposition to Disease<br/>Germ-Line Mutation<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Pedigree<br/>Piperidines--administration & dosage<br/>Protein Kinase Inhibitors--administration & dosage<br/>Proto-Oncogene Mas<br/>Proto-Oncogene Proteins c-ret--antagonists & inhibitors<br/>Quinazolines--administration & dosage<br/>Risk Factors<br/>Thyroid Neoplasms--drug therapy<br/>Time Factors<br/>Treatment Outcome<br/>United States<br/>Young Adult